Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD

Blood (2019) 134 (Supplement_1): 5869.

https://doi.org/10.1182/blood-2019-124990

Published: 2019

Journal Articles

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Marshall McKenna, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 3316.

https://doi.org/10.1182/blood-2019-132114

Published: 2019

Journal Articles

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Kimberly Amelsberg, Nisha Joseph, MD, Amelia Langston, MD, Jonathan L Kaufman, MD, Craig C Hofmeister, MD MPH, Edmund K. Waller, MD, Michael Graiser, PhD, Robin Larocco, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2018-99-119730

Published: 2018

Journal Articles

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Gunjan L. Shah, MD, Heather Landau, MD, Caitlin Sarubbi, A.B, Ryan Schofield, MS, Andrew Lin, PharmD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Sean M. Devlin, PhD, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD

Blood (2017) 130 (Supplement 1): 3296.

https://doi.org/10.1182/blood.V130.Suppl_1.3296.3296

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Amanda F. Cashen, MD, Kendall Gosch, BA, Theresa Fletcher, MS, Connie Ceriotti, RN, BSN, Armin Ghobadi, MD, Ravi Vij, MD, Keith Stockerl-Goldstein, MD, John F Dipersio, MD PhD, Camille N Abboud, MD

Blood (2015) 126 (23): 3196.

https://doi.org/10.1182/blood.V126.23.3196.3196

Published: 2015

Journal Articles

Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation

Omar S. Aljitawi, MD, Anna Ludlow, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Tara Lin, MD, J.D Pipkin, PhD, Joseph McGuirk, DO

Blood (2012) 120 (21): 4551.

https://doi.org/10.1182/blood.V120.21.4551.4551

Published: 2012

Journal Articles

Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Omar S. Aljitawi, MD, Sunil Abhyankar, MD, Siddhartha Ganguly, MD, Karen Wolfe, Kelly Daniels, Ron Marks, Mike Ferree, J.D. Pipkin, PhD, Joseph McGuirk, DO

Blood (2011) 118 (21): 4512.

https://doi.org/10.1182/blood.V118.21.4512.4512

Published: 2011

Journal Articles

Efficacy and Tolerability of CEP-18770 in Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM)

Eric Sanchez, Cydney M Nichols, Alison C Lam, Mingjie Li, Jennifer Li, Cathy Wang, Colsen A Beveridge, Jacob T Lista, Haiming Chen, James R. Berenson, MD

Blood (2011) 118 (21): 2946.

https://doi.org/10.1182/blood.V118.21.2946.2946

Published: 2011

Journal Articles

A Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Studyof Melphalan HCl for Injection (propylene glycol-free) and Alkeran for Injection for Myeloablative Conditioning In Multiple Myeloma Patients Undergoing Autologous Transplantation.

Omar Aljitawi, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, J. Daniel Robinson, J, D. Pipkin, Joseph McGuirk, DO

Blood (2010) 116 (21): 4525.

https://doi.org/10.1182/blood.V116.21.4525.4525

Published: 2010

Journal Articles

Efficacy and Tolerability of CEP-18770 In Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM)

Eric Sanchez, Mingjie Li, Cathy Wang, Zhi-Wei Li, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD

Blood (2010) 116 (21): 4066.

https://doi.org/10.1182/blood.V116.21.4066.4066

Published: 2010

NARROW

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation

Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Efficacy and Tolerability of CEP-18770 in Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM)

A Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Studyof Melphalan HCl for Injection (propylene glycol-free) and Alkeran for Injection for Myeloablative Conditioning In Multiple Myeloma Patients Undergoing Autologous Transplantation.

Efficacy and Tolerability of CEP-18770 In Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only